Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Free Cash Flow: 2021-2025

Historic Free Cash Flow for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to -$41.5 million.

  • ARS Pharmaceuticals' Free Cash Flow fell 184.29% to -$41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.0 million, marking a year-over-year decrease of 86.87%. This contributed to the annual value of $13.0 million for FY2024, which is 121.85% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Free Cash Flow stood at -$41.5 million, which was up 8.45% from -$45.4 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Free Cash Flow ranged from a high of $41.7 million in Q4 2024 and a low of -$45.4 million during Q2 2025.
  • Over the past 3 years, ARS Pharmaceuticals' median Free Cash Flow value was -$14.6 million (recorded in 2024), while the average stood at -$15.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 340.86% in 2024, then tumbled by 519.94% in 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Free Cash Flow (Quarterly) stood at $28.7 million in 2021, then tumbled by 171.95% to -$20.6 million in 2022, then increased by 16.05% to -$17.3 million in 2023, then soared by 340.86% to $41.7 million in 2024, then tumbled by 184.29% to -$41.5 million in 2025.
  • Its last three reported values are -$41.5 million in Q3 2025, -$45.4 million for Q2 2025, and -$40.8 million during Q1 2025.